About Allergan PLC. (NYSE:AGN)
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:AGN
- CUSIP: 01849010
- Web: www.allergan.com
- Market Cap: $62.94 billion
- Outstanding Shares: 334,306,000
- 50 Day Moving Avg: $212.48
- 200 Day Moving Avg: $230.71
- 52 Week Range: $182.80 - $256.80
Sales & Book Value:
- Trailing P/E Ratio: 5.74
- Foreward P/E Ratio: 10.95
- P/E Growth: 1.03
- Annual Revenue: $15.07 billion
- Price / Sales: 4.18
- Book Value: $210.39 per share
- Price / Book: 0.89
- Annual Dividend: $2.80
- Dividend Yield: 1.4%
- EBITDA: $6.15 billion
- Net Margins: 79.17%
- Return on Equity: 7.37%
- Return on Assets: 4.17%
- Debt-to-Equity Ratio: 0.38%
- Current Ratio: 1.21%
- Quick Ratio: 1.10%
- Average Volume: 2.77 million shs.
- Beta: 1.15
- Short Ratio: 3.43
Frequently Asked Questions for Allergan PLC. (NYSE:AGN)
What is Allergan PLC.'s stock symbol?
Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?
Allergan PLC. announced a quarterly dividend on Wednesday, August 2nd. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share on Friday, September 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.49%. The ex-dividend date is Wednesday, August 16th. View Allergan PLC.'s Dividend History.
How will Allergan PLC.'s stock buyback program work?
Allergan PLC. announced that its board has approved a share buyback program on Tuesday, September 26th 2017, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its stock is undervalued.
How were Allergan PLC.'s earnings last quarter?
Allergan PLC. (NYSE:AGN) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.95 by $0.07. The business earned $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business's revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 EPS. View Allergan PLC.'s Earnings History.
When will Allergan PLC. make its next earnings announcement?
What guidance has Allergan PLC. issued on next quarter's earnings?
Allergan PLC. issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $16.05-16.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.08. The company issued revenue guidance of $15.85-16.05 billion, compared to the consensus revenue estimate of $15.81 billion.
Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?
19 analysts have issued 12 month price targets for Allergan PLC.'s stock. Their forecasts range from $193.00 to $280.00. On average, they expect Allergan PLC.'s share price to reach $251.76 in the next year. View Analyst Ratings for Allergan PLC..
What are analysts saying about Allergan PLC. stock?
Here are some recent quotes from research analysts about Allergan PLC. stock:
- 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi and Vraylar, are supporting sales growth. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, Allergan is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio, which concerns us. In October, a Texas federal district court invalidated four of the six patents covering Restasis, Allergan’s second best-selling drug, potentially opening doors for early generic competition. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares have underperformed the broader industry in the past one month. Estimates have also declined slightly ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/17/2017)
- 2. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
- 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
Who are some of Allergan PLC.'s key competitors?
Some companies that are related to Allergan PLC. include Novo Nordisk A/S (NVO), Sanofi (SNY), Bayer AG (BAYRY), Medtronic PLC (MDT), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Celgene Corporation (CELG), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), Thermo Fisher Scientific (TMO), Biogen (BIIB), Stryker Corporation (SYK), Aetna (AET), Anthem (ANTM), Becton, Dickinson and Company (BDX) and Fresenius SE (FSNUY).
Who owns Allergan PLC. stock?
Allergan PLC.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.10%), Cacti Asset Management LLC (0.07%), Sit Investment Associates Inc. (0.03%), Verde Servicos Internacionais S.A. (0.03%), PGGM Investments (0.02%) and Park National Corp OH (0.01%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..
Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?
Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Bridges Investment Counsel Inc., Sit Investment Associates Inc., Verde Servicos Internacionais S.A., Howe & Rusling Inc., Windward Capital Management Co. CA and Bristlecone Advisors LLC. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..
Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?
Allergan PLC.'s stock was bought by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, Robeco Institutional Asset Management B.V., Assenagon Asset Management S.A., Sumitomo Life Insurance Co., Park National Corp OH, Wealth Enhancement Advisory Services LLC, Fisher Asset Management LLC and Meeder Asset Management Inc.. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders and Maria Teresa Hilado. View Insider Buying and Selling for Allergan PLC..
How do I buy Allergan PLC. stock?
Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan PLC.'s stock price today?
MarketBeat Community Rating for Allergan PLC. (NYSE AGN)MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Allergan PLC. stock can currently be purchased for approximately $188.28.
Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||8 Hold Ratings, 11 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.58)|
|Consensus Price Target: ||$251.76 (33.72% upside)|Consensus Price Target History for Allergan PLC. (NYSE:AGN)
Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
(Data available from 10/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/20/2017||Cowen and Company||Set Price Target||Buy||$400.00 -> $280.00||N/A|
|10/19/2017||Royal Bank Of Canada||Reiterated Rating||Outperform -> Outperform||$277.00 -> $250.00||N/A|
|10/19/2017||Citigroup Inc.||Lower Price Target||Buy||$280.00 -> $240.00||N/A|
|10/19/2017||Mizuho||Downgrade||Buy -> Neutral||$193.00 -> $193.00||N/A|
|10/18/2017||Edward Jones||Reiterated Rating||Buy -> Hold||N/A|
|10/18/2017||Sanford C. Bernstein||Set Price Target||Buy||$296.00 -> $252.00||N/A|
|10/18/2017||Wells Fargo & Co||Reiterated Rating||Outperform||$258.00||N/A|
|10/17/2017||Deutsche Bank AG||Set Price Target||Buy||$251.00||N/A|
|10/17/2017||Credit Suisse Group||Set Price Target||Outperform||$266.00 -> $243.00||N/A|
|10/16/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||$275.00||N/A|
|10/13/2017||Piper Jaffray Companies||Set Price Target||Hold||$227.00||N/A|
|10/12/2017||Cantor Fitzgerald||Set Price Target||Hold||$231.00||N/A|
|10/2/2017||Barclays PLC||Reiterated Rating||Equal Weight||Low|
|9/20/2017||Morgan Stanley||Downgrade||Overweight -> Equal Weight||$284.00 -> $228.00||Medium|
|5/10/2017||Goldman Sachs Group, Inc. (The)||Downgrade||Buy -> Neutral||$262.00||High|
|2/9/2017||Leerink Swann||Boost Price Target||Buy||$280.00||N/A|
|12/23/2016||Bank of America Corporation||Reiterated Rating||Buy||$280.00||N/A|
|11/21/2016||William Blair||Reiterated Rating||Market Perform||N/A|
|4/12/2016||S&P Equity Research||Reiterated Rating||Buy||N/A|
|4/7/2016||Raymond James Financial, Inc.||Lower Price Target||Outperform||$317.00 -> $275.00||N/A|
|4/7/2016||Canaccord Genuity||Reiterated Rating||Buy||N/A|
|4/7/2016||Susquehanna Bancshares Inc||Downgrade||Positive -> Neutral||$345.00 -> $275.00||N/A|
|4/5/2016||Nomura||Reiterated Rating||Buy||$350.00 -> $330.00||N/A|
Earnings History for Allergan PLC. (NYSE:AGN)Earnings History by Quarter for Allergan PLC. (NYSE AGN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||$3.95||$4.02||$3.95 billion||$4.01 billion||View||Listen|
|5/9/2017||Q1 2017||$3.32||$3.35||$3.53 billion||$3.57 billion||View||Listen|
|2/8/2017||Q416||$3.76||$3.90||$3.77 billion||$3.86 billion||View||Listen|
|11/2/2016||Q316||$3.57||$3.32||$3.73 billion||$3.62 billion||View||Listen|
|8/8/2016||Q216||$3.34||$3.35||$4.10 billion||$3.68 billion||View||Listen|
|5/10/2016||Q116||$3.03||$3.04||$3.97 billion||$3.80 billion||View||Listen|
|2/22/2016||Q415||$3.36||$3.41||$4.20 billion||$4.20 billion||View||Listen|
|11/4/2015||Q315||$3.20||$3.48||$5.71 billion||$4.10 billion||View||N/A|
|8/6/2015||Q215||$4.41||$4.41||$5.71 billion||$5.76 billion||View||N/A|
|11/5/2014||Q414||$1.83||$2.17||$1.90 billion||$1.91 billion||View||N/A|
|8/5/2014||Q314||$1.76||$1.78||$1.78 billion||$1.79 billion||View||Listen|
|7/21/2014||Q214||$1.44||$1.51||$1.77 billion||$1.83 billion||View||N/A|
|4/30/2014||Q114||$1.13||$1.18||$1.60 billion||$1.65 billion||View||N/A|
|2/4/2014||Q413||$1.34||$1.12||$1.65 million||$1.66 million||View||N/A|
|10/29/2013||Q313||$1.20||$1.23||$1.53 billion||$1.23 billion||View||Listen|
|7/31/2013||Q2 2013||$1.20||$1.22||$1.56 billion||$1.60 billion||View||N/A|
|5/1/2013||Q1 2013||$0.96||$0.98||$1.44 billion||$1.46 billion||View||N/A|
|2/5/2013||Q4 2012||$1.20||$1.15||$1.51 million||$1.48 million||View||N/A|
|10/30/2012||Q312||$1.04||$1.06||$1.43 billion||$1.39 billion||View||N/A|
Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.31
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Allergan PLC. (NYSE:AGN)
|Most Recent Dividend:||9/15/2017|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||9.95% (Trailing 12 Months of Earnings) |
17.27% (Based on This Year's Estimates)
16.28% (Based on Next Year's Estimates)
Dividend History by Quarter for Allergan PLC. (NYSE AGN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)
Insider Ownership Percentage: 0.36%Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership Percentage: 81.94%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/18/2017||Nesli Basgoz||Director||Sell||1,889||$220.45||$416,430.05|| |
|3/2/2017||Paul Bisaro||Director||Sell||70,000||$246.68||$17,267,600.00|| |
|12/8/2016||Nesli Basgoz||Director||Sell||500||$188.72||$94,360.00|| |
|11/21/2016||Brent L. Saunders||CEO||Buy||5,250||$189.13||$992,932.50|| |
|11/11/2016||Maria Teresa Hilado||CFO||Buy||1,422||$210.64||$299,530.08|| |
|6/2/2016||Maria Teresa Hilado||CFO||Buy||661||$241.57||$159,677.77|| |
|5/11/2016||Nesli Basgoz||Director||Sell||459||$225.10||$103,320.90|| |
|12/7/2015||Nesli Basgoz||Director||Sell||2,300||$312.96||$719,808.00|| |
|8/24/2015||Paul Bisaro||Chairman||Buy||1,000||$297.42||$297,420.00|| |
|8/21/2015||Brent L Saunders||CEO||Buy||1,000||$301.94||$301,940.00|| |
|4/22/2014||Scott Sherman||EVP||Sell||14,500||$155.82||$2,259,390.00|| |
|2/21/2014||Louis Lavigne, Jr.||Director||Sell||5,400||$125.79||$679,266.00|| |
|2/19/2014||Dawn Hudson||Director||Sell||4,200||$126.35||$530,670.00|| |
|2/19/2014||Jeffrey Edwards||CFO||Sell||38,900||$126.39||$4,916,571.00|| |
|2/19/2014||Raymond Diradoorian||EVP||Sell||23,000||$126.66||$2,913,180.00|| |
|2/18/2014||Scott Sherman||EVP||Sell||5,001||$125.74||$628,825.74|| |
|1/14/2014||Scott Whitcup||VP||Sell||42,000||$117.80||$4,947,600.00|| |
|12/27/2013||Julian Gangolli||VP||Sell||52,500||$110.05||$5,777,625.00|| |
|12/20/2013||Scott Whitcup||VP||Sell||33,000||$108.80||$3,590,400.00|| |
|10/15/2013||Trevor Jones||Director||Sell||2,000||$90.14||$180,280.00|| |
|9/16/2013||Trevor Jones||Director||Sell||2,000||$89.78||$179,560.00|| |
|8/15/2013||Trevor Jones||Director||Sell||2,000||$89.89||$179,780.00|| |
|8/6/2013||Jeffrey Edwards||CFO||Sell||69,200||$91.17||$6,308,964.00|| |
|7/15/2013||Trevor M Jones||Director||Sell||2,000||$91.15||$182,300.00|| |
|6/17/2013||Trevor M Jones||Director||Sell||2,000||$101.25||$202,500.00|| |
|5/15/2013||Trevor M Jones||Director||Sell||2,000||$103.40||$206,800.00|| |
|5/9/2013||Jeffrey L Edwards||CFO||Sell||84,000||$103.49||$8,693,160.00|| |
|11/26/2012||Trevor M Jones||Director||Sell||2,500||$91.30||$228,250.00|| |
|10/5/2012||David E I Pyott||CEO||Sell||616,300||$93.73||$57,765,799.00|| |
Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
Allergan PLC. (AGN) Chart for Friday, October, 20, 2017